What's in Amarantus BioScience Holdings, Inc.'s pipeline?

Amarantus BioScience Holdings, Inc. has 2 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with Amarantus BioScience Holdings, Inc.'s portfolio?

Top competitors by shared drug class: CUTISS AG, Massachusetts General Hospital, zhang li.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/amarantus-bioscience-holdings-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Amarantus BioScience Holdings, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Amarantus BioScience Holdings, Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Dermatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

CUTISS AG · 1 shared drug class
Massachusetts General Hospital · 1 shared drug class
zhang li · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Amarantus BioScience Holdings, Inc.:

Cite this brief

Drug Landscape (2026). Amarantus BioScience Holdings, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/amarantus-bioscience-holdings-inc. Accessed 2026-05-16.